WO2016158212A1 - Food composition containing resveratrol and nicotinamide mononucleotide - Google Patents
Food composition containing resveratrol and nicotinamide mononucleotide Download PDFInfo
- Publication number
- WO2016158212A1 WO2016158212A1 PCT/JP2016/056943 JP2016056943W WO2016158212A1 WO 2016158212 A1 WO2016158212 A1 WO 2016158212A1 JP 2016056943 W JP2016056943 W JP 2016056943W WO 2016158212 A1 WO2016158212 A1 WO 2016158212A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- food composition
- blood
- resveratrol
- composition according
- nicotinamide
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
Definitions
- the present invention relates to a food composition containing resveratrol and nicotinamide mononucleotide.
- lifestyle-related diseases such as obesity, hyperlipidemia, diabetes and hypertension.
- lifestyle-related diseases have genetic elements, they are mainly caused by disordered lifestyles in daily life. Factors such as diet, exercise, drinking, smoking and stress are closely related to lifestyle-related diseases.
- Factors such as diet, exercise, drinking, smoking and stress are closely related to lifestyle-related diseases.
- dietary habits that consume high-calorie, high-fat foods have become commonplace. It is thought to have a big influence. Therefore, in order to prevent lifestyle-related diseases or cure them while the symptoms are mild and maintain health, it is important to feed a diet with a well-balanced nutritional balance.
- Resveratrol is a type of stilbenoid polyphenol that functions as phytoalexin in some plants and is also found in grape skins, red wine, peanut skins, itadori, gnemon, etc. .
- Resveratrol is known for its various physiological functions such as life-spanning action, female hormone action, antioxidant action, tyrosinase activity inhibitory action, antibacterial action, metabolic syndrome improving action, neuroprotective action, It is a functional ingredient that has attracted a great deal of attention.
- Non- Patent Documents 1 and 2 Clinical studies on the effectiveness of resveratrol have reported improvement in vasodilator response, prevention of arteriosclerosis, and prevention of dementia by increasing cerebral blood flow in subjects with high blood pressure.
- Non-patent Document 3 since a decrease in blood growth factor IGF-1 and its binding protein IGFBP-3 has been observed, the possibility of reducing the risk of breast cancer and lung cancer has been reported (Non-patent Document 3).
- reports have been made on the energy consumption, metabolic rate, blood glucose level, blood pressure reduction and the like of obese men (Non-patent Document 4).
- compositions containing resveratrol have been reported.
- a pharmaceutical composition containing maltitol and resveratrol for the prevention and / or treatment of liver dysfunction (Patent Document 1). ), A metabolic promoter composition comprising two resveratrol derivatives having a predetermined structure as an active ingredient (Patent Document 2), a blood pressure-lowering agent containing transresveratrol in a plant extract containing ⁇ -viniferin ( Patent Document 3), resveratrol obtained by extraction with a polar solvent having 1 to 5 carbon atoms from buds and vines of plants belonging to European grape genus (Vitis Vinifera) and / or American grapevine (Vitis Labrusca) 5 ⁇ -reductase inhibitor, hyaluronidase inhibitor, elastase inhibitor, fibroblast proliferating agent, coller Production promoter or lipase inhibitor (Patent Document 4), and active ingredient includes resveratrol or its
- resveratrol has a physiological effect that is considered to be useful in preventing lifestyle-related diseases and maintaining health, that is, an antioxidant effect and a normalizing action of blood sugar level. Has been reported. Therefore, many food compositions containing resveratrol are on the market in expectation of the effect of such physiological action.
- an object of the present invention is to provide a resveratrol-containing food composition that is effective in preventing and improving lifestyle-related diseases and maintaining a healthy body state.
- resveratrol with nicotinamide mononucleotide, which is an intermediate metabolite involved in the biosynthesis of coenzyme NAD (nicotinamide adenine dinucleotide).
- the present invention is a food composition containing resveratrol and nicotinamide mononucleotide.
- the food composition of the present invention is capable of orienting each value of blood total cholesterol, low-density lipoprotein cholesterol, neutral fat, and uric acid exceeding the proper reference range in the normal direction. It is very effective in preventing and ameliorating the disease and maintaining a healthy body condition.
- the food composition of the present invention is characterized by containing resveratrol and nicotinamide mononucleotide, and by using both in combination, total cholesterol in blood, low density lipoprotein cholesterol, neutral fat, and uric acid Effectively normalizes each value.
- Resveratrol (chemical formula: C 14 H 12 O 3 ) contained in the food composition of the present invention is a compound represented by the following structural formula [Chemical Formula 1], and as described above, grape skin and red wine It is known as an antioxidant contained in peanut skin, itadori, gnemon, and the like.
- Resveratrol used in the present invention includes resveratrol derivatives such as trans and cis isomers, trans-cis isomer mixtures, dimers, and methylated resveratrol. Usually, heat-stable trans isomers are used for health foods and the like.
- Resveratrol may be synthetically prepared in addition to those prepared by extraction and purification from any starting material. Many methods for producing resveratrol have been reported.
- styrene derivatives using 3,5-dihydroxybenzoic acid as a starting material protection of phenolic hydroxyl groups with acetyl groups, conversion to acid chlorides, and palladium catalysts.
- There are known methods such as coupling with water, deprotection by hydrolysis, and hydrolyzing by Heck coupling of 3,5-diacetoxystyrene and p-acetoxyiodobenzene using a palladium catalyst.
- resveratrol is marketed and those commercial items can be purchased and used.
- Nicotinamide mononucleotide contained in the food composition of the present invention is a compound represented by the following structural formula [Chemical Formula 2], and generally NMN (Nicotinamide mononucleotide) And is known as an intermediate metabolite involved in the biosynthesis of the coenzyme NAD + . In vivo, it is produced in the NAD metabolic pathway by the liver tissue, that is, the pathway toward synthesis of nicotinamide adenine dinucleotide (NAD) from quinolinic acid via the kynurenine pathway. This point will be specifically described with reference to FIG.
- NAD nicotinamide adenine dinucleotide
- tryptophan when tryptophan is used as a starting material, tryptophan is converted into quinolinic acid (QA) via the kynurenine pathway, which is a tryptophan metabolic pathway, and further converted into nicotinic acid mononucleotide (NaMN).
- QA quinolinic acid
- NaMN nicotinic acid mononucleotide
- nicotinic acid (Na) when nicotinic acid (Na) is used as a starting material, nicotinic acid is directly converted to NaMN. NaMN is then converted into NAD, nicotinamide (NaM), and nicotinamide mononucleotide by the NAD cycle via nicotinic acid adenine dinucleotide (NaAD).
- Nicotinamide (NaM) is converted to nicotinamide mononucleotide by nicotinamide phosphoribosyltransferase (NAMPT), which is then converted by nicotinamide mononucleotide adenyltransferase (NMNAT) to produce NAD. Nicotinamide mononucleotide is also produced from nicotinamide riboside (NR).
- NAMPT nicotinamide phosphoribosyltransferase
- NMNAT nicotinamide mononucleotide adenyltransferase
- Nicotinamide mononucleotide is also produced from nicotinamide riboside (NR).
- Nicotinamide mononucleotide has two types of ⁇ isomers and ⁇ isomers as optical isomers, and ⁇ isomers are used in the present invention. Nicotinamide mononucleotide is prepared, for example, by synthesizing nicotinamide riboside from nicotinamide and ribose (see Bioorg. Med. Chem. Lett., 12, 1135-1137 (2002)), and then the 5-position hydroxyl group of the ribose moiety. It can be obtained by phosphorylation (see Chem. Comm., 1999, 729-730).
- nicotinamide and L-ribose tetraacetate are dissolved in anhydrous acetonitrile, an excess amount of trimethylsilyl trifluorosulfonic acid is added under a nitrogen stream, and the mixture is stirred at room temperature and methanol is added.
- the reaction solution whose reaction has been stopped is applied to a column filled with activated carbon, washed with distilled water, and eluted with methanol to recover the product.
- nicotinamide mononucleotide is commercially available, and those commercially available products can be purchased and used.
- the ratio of resveratrol and nicotinamide mononucleotide is not limited, but from the viewpoint of maximizing the effects of the present invention, It is preferable to adjust the blending ratio of both so that resveratrol is 1 to 100 parts by mass and nicotinamide mononucleotide is 1 to 25 parts by mass.
- the food composition of the present invention further includes one or more selected from the group consisting of tryptophan and niacin (vitamin B3; generic name for nicotinic acid and nicotinamide) and metabolites thereof. It is preferable. Thereby, the effect of improving the neutral fat level in the blood is further enhanced. The reason for this enhancement is unclear, but it is thought that intracellular energy metabolism is related because tryptophan, niacin, and most of their metabolites function as coenzymes for in vivo redox reactions.
- niacin examples include nicotinic acid adenine dinucleotide, nicotinic acid mononucleotide, nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate, nicotinamide riboside and ADP ribose.
- the food composition of the present invention includes nutritional supplements, excipients, binders, dispersants, lubricants, disintegrants, emulsifiers, solubilizers, pH adjusters, antioxidants, taste
- An improving agent or the like can be appropriately added within a range that does not impair the effects of the present invention.
- Examples of the nutritional supplement component include amino acids, minerals, vitamins, coenzymes, plant extracts, collagen, elastin, peptides, mucopolysaccharides (hyaluronic acid, chondroitin, etc.) and the like.
- excipient examples include lactose, sucrose, fructose, glucose, glucose hydrate, sucrose, purified sucrose, xylitol, sorbitol, mannitol, palatinose, reduced palatinose, powdered maltose, water candy, carmellose, dextrin, corn starch , Pregelatinized starch, partially pregelatinized starch, potato starch, corn starch, hydroxypropyl starch, amino acid, kaolin, silicic anhydride, silicic acid, aluminum silicate, sodium bicarbonate, calcium phosphate, calcium dihydrogen phosphate, calcium carbonate, oxidation Magnesium, aluminum hydroxide, fatty acid or salt thereof, fatty acid monoglyceride and diglyceride, various spirits, olive oil, soybean oil, corn oil, fatty oil, oil and fat, propylene glycol, Glycol, polyethylene glycol, glycerol and the like.
- binder examples include crystalline cellulose, crystalline cellulose / carmellose sodium, methylcellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carmellose sodium, ethylcellulose , Carboxymethyl ethyl cellulose, hydroxyethyl cellulose, wheat starch, rice starch, corn starch, potato starch, pregelatinized starch, partially pregelatinized starch, hydroxypropyl starch, dextrin, pullulan, polyvinylpyrrolidone, aminoalkyl methacrylate copolymer E, aminoalkyl methacrylate Over copolymer RS, methacrylic acid copolymer L, methacrylic acid copolymer, polyvinyl acetal diethylamino acetate, polyvinyl alcohol, gum arabic, gum arabic powder,
- dispersant or lubricant examples include magnesium stearate, calcium stearate, stearic acid, hydrous silicon dioxide, sucrose fatty acid ester, wheat starch, rice starch, corn starch, synthetic aluminum silicate, dry aluminum hydroxide gel, and metasilicic acid.
- examples thereof include magnesium aluminate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, hydrogenated vegetable oil, polyethylene glycol, light anhydrous silicic acid, synthetic aluminum silicate, macrogol, talc and the like.
- disintegrant examples include crystalline cellulose, methylcellulose, low-substituted hydroxypropylcellulose, carmellose, carmellose calcium, carmellose sodium, croscarmellose sodium, wheat starch, rice starch, corn starch, potato starch, partially pregelatinized starch, Examples include hydroxypropyl starch, carboxymethyl starch sodium, tragacanth and the like.
- emulsifier examples include soybean lecithin, sucrose fatty acid ester, polyoxyl stearate, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, sorbitan sesquioleate, sorbitan trioleate, sorbitan monostearate, monopalmitic acid
- examples include sorbitan, sorbitan monolaurate, polysorbate, glyceryl monostearate, sodium lauryl sulfate, lauromacrogol and the like.
- solubilizer examples include sodium phosphate, polysorbates
- the pH adjuster includes citric acid, sodium citrate, acetic acid, tartaric acid, sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium carbonate, lactic acid
- examples of the antioxidant include ascorbic acid, erythorbic acid, catechin
- examples of the taste improver include various fruit juices and vegetable extracts.
- cranberry juice orange juice, acerola juice, grape juice, apple juice, peach juice, muscat juice, pineapple juice, lychee juice, raspberry juice, pomegranate juice, kiwifruit juice, cherry juice, blueberry
- beverage substrates such as fruit juice, lotus cup juice, grapefruit juice, and lime juice.
- the method for producing the food composition of the present invention is not particularly limited, and a general production method used for producing the food composition may be appropriately selected according to the form of the food composition.
- the form of the food composition is a powder, it can be produced by uniformly kneading resveratrol, nicotinamide mononucleotide, and other components blended as necessary. What is necessary is just to determine the compounding quantity of each component suitably.
- resveratrol and nicotinamide mononucleotide which are essential components, are commercially available and can be obtained commercially.
- nicotinamide mononucleotide the quality control system and mass production system of nicotinamide mononucleotide have been established in recent years, and supply as a food composition raw material has become possible. It has been confirmed.
- the food composition of the present invention is provided as various foods and beverages. In that case, it can be processed and provided in the same form as general dietary supplements, that is, powders, tablets, pills, granules, hard capsules, soft capsules, jellies, liquids, pastes and the like.
- the daily intake amount of resveratrol contained in the food composition is usually 1 mg to 1000 mg, preferably 1 mg to 500 mg, more preferably 1 mg to 100 mg. is there. If the amount is less than 1 mg, the effect of the present invention may not be obtained. On the other hand, if the amount is more than 1000 mg, the obtained effect is not particularly changed, which is economically disadvantageous.
- the food composition of the present invention is useful in preventing and improving lifestyle-related diseases, but can be preferably used as a food composition for reducing total cholesterol in blood. That is, by ingesting the food composition of the present invention, total cholesterol in the blood exceeding the appropriate reference range can be reduced.
- Cholesterol is an important component that is made in the liver and forms cell membranes and generates bile acids and sex hormones that help digest fat in the intestines. Increased chance of causing arteriosclerosis.
- the incidence of ischemic heart diseases such as myocardial infarction is said to correlate with blood cholesterol.
- the total cholesterol level in the blood is 130 to 219 mg / dL, but as shown in the examples described later, the food composition of the present invention is continuously ingested for a certain period of time. By doing so, the total cholesterol value higher than the reference range can be reduced.
- the food composition of the present invention can be preferably used as a food composition for reducing low specific gravity lipoprotein cholesterol in blood. That is, by ingesting the food composition of the present invention, low-density lipoprotein cholesterol (LDL cholesterol) in blood exceeding the appropriate reference range can be reduced. Low density lipoprotein cholesterol is transported from the liver to whole body tissues, but if it is too much, it accumulates in the arterial wall and promotes arteriosclerosis, so it is also called bad cholesterol.
- the low specific gravity lipoprotein cholesterol level in the blood is approximately 65 to 139 mg / dL as a rough standard, but as shown in the examples described later, the food composition of the present invention is continuously added. By ingesting for a certain period of time, a low specific gravity lipoprotein cholesterol level higher than the reference range can be reduced.
- the food composition of the present invention can be preferably used as a food composition for reducing neutral fat in blood. That is, by ingesting the food composition of the present invention, it is possible to reduce the neutral fat in the blood that exceeds the appropriate reference range.
- Neutral fat is absorbed in the small intestine after food intake and enters the blood to be used as an energy source, but if it is too much, it can cause obesity, fatty liver, diabetes, etc. Because it leads to an increase, it promotes arteriosclerosis and becomes a base for stroke and heart disease.
- the blood neutral fat level is 30 to 149 mg / dL as a reference range.
- the food composition of the present invention is continuously applied for a certain period of time. By ingesting, a neutral fat value higher than the reference range can be reduced.
- the food composition of the present invention can be preferably used as a food composition for reducing uric acid in blood. That is, by ingesting the food composition of the present invention, uric acid in the blood exceeding the appropriate reference range can be reduced.
- Uric acid is a waste product made by decomposing DNA constituting the gene and ATP responsible for energy, but if it is too much, it can cause gout, kidney damage, urinary calculus, etc., metabolic syndrome, hypertension, lipid It becomes easy to combine life-style related diseases such as abnormalities and diabetes.
- the uric acid level in the blood is roughly set as the reference value range for males 3.8 to 7.0 mg / dL and females 2.5 to 7.0 mg / dL. As described above, by continuously ingesting the food composition of the present invention for a certain period, it is possible to reduce the uric acid value higher than the reference value range.
- the food composition of the present invention can be taken regardless of gender.
- it is suitably applied to middle-aged and elderly people whose blood total cholesterol, low-density lipoprotein cholesterol, neutral fat, and uric acid values exceed the appropriate reference range.
- the intake period is not limited, but in order to make the total cholesterol, low density lipoprotein cholesterol, neutral fat, and uric acid values that exceed the appropriate reference range normal, take them for a long period of time. It is preferable to take it continuously every day for at least about 4 weeks.
- Example 1 440 mg of excipients (starch, calcium stearate, fine silicon dioxide) are added to 20 mg of resveratrol and 20 mg of ⁇ -nicotinamide mononucleotide and kneaded homogeneously, and the resulting product is filled into a commercially available hard capsule This produced a hard capsule.
- excipients starch, calcium stearate, fine silicon dioxide
- Example 2 To resveratrol 20 mg, ⁇ -nicotinamide mononucleotide 20 mg, and niacinamide 120 mg, 340 mg of excipients (starch, calcium stearate, fine silicon dioxide) were added and kneaded uniformly, and the resulting product was commercially available. A hard capsule was prepared by filling the hard capsule.
- each hard capsule prepared in Examples 1 and 2 was given to 3 subjects (50s) each with a high total blood cholesterol level, once a day with 2 capsules, water or lukewarm water once a day (dinner It was ingested continuously for 4 weeks (28 days) at the frequency of (before).
- each hard capsule prepared in Comparative Examples 1 and 2 was given to two subjects (in their 50s) each with a high total blood cholesterol level once daily with 2 capsules, water, or lukewarm water. It was ingested continuously for 4 weeks (28 days) at a frequency of (before dinner).
- each hard capsule prepared in Examples 1 and 2 was given to 3 subjects (50s) each with high blood low density lipoprotein cholesterol, once daily with 2 capsules, water or lukewarm water. It was ingested continuously for 4 weeks (28 days) at a frequency of (before dinner).
- each hard capsule prepared in Comparative Examples 1 and 2 was given to two subjects (in their 50s) each with high low-density lipoprotein cholesterol in the blood each day with 2 capsules, water, or lukewarm water for 1 day. It was ingested continuously at a frequency of once (before dinner) for 4 weeks (28 days).
- LDL cholesterol low density lipoprotein cholesterol
- each of the hard capsules prepared in Examples 1 and 2 was given to 3 subjects (in their 50s) each with a high blood neutral fat level once a day with 2 capsules, water or lukewarm water at a time ( It was ingested continuously for 4 weeks (28 days) at a frequency of (before dinner).
- each hard capsule prepared in Comparative Examples 1 and 2 was given to two subjects (in their 50s) each with a high blood neutral fat level, with 2 capsules, water or lukewarm water per day. It was ingested continuously for 4 weeks (28 days) at a frequency of twice (before dinner).
- each hard capsule prepared in Example 1 was given to two subjects (in their 50s) with high blood uric acid levels once a day (before dinner) with 2 capsules, water or lukewarm water each time. For 4 weeks (28 days).
- each hard capsule prepared in Comparative Examples 1 and 2 was given to two subjects (in their 50s) each with a high blood uric acid level once a day with 2 capsules, water or lukewarm water at a time ( It was ingested continuously for 4 weeks (28 days) at a frequency of (before dinner).
- Example 1 As can be seen from the results shown in Table 4, when the hard capsule prepared in Example 1 was ingested, it was recognized that the uric acid value significantly decreased. On the other hand, when the hard capsules prepared in Comparative Examples 1 and 2 were ingested, an increase in the uric acid level was observed in both cases. From this, the food composition of Example 1 containing resveratrol and nicotinamide mononucleotide has an effect that cannot be predicted from the food compositions of Comparative Examples 1 and 2, that is, an effect of reducing the concentration of uric acid in blood. It was confirmed.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
レスベラトロール20mg、及びβ-ニコチンアミドモノヌクレオチド20mgに対し、賦形剤(デンプン、ステアリン酸カルシウム、微粒二酸化ケイ素)440mgを加えて均質に混練し、得られた生成物を市販のハードカプセルに充填することにより、ハードカプセル剤を作製した。 (Example 1)
440 mg of excipients (starch, calcium stearate, fine silicon dioxide) are added to 20 mg of resveratrol and 20 mg of β-nicotinamide mononucleotide and kneaded homogeneously, and the resulting product is filled into a commercially available hard capsule This produced a hard capsule.
レスベラトロール20mg、β-ニコチンアミドモノヌクレオチド20mg、及びナイアシンアミド120mgに対し、賦形剤(デンプン、ステアリン酸カルシウム、微粒二酸化ケイ素)340mgを加えて均質に混練し、得られた生成物を市販のハードカプセルに充填することにより、ハードカプセル剤を作製した。 (Example 2)
To resveratrol 20 mg, β-nicotinamide mononucleotide 20 mg, and niacinamide 120 mg, 340 mg of excipients (starch, calcium stearate, fine silicon dioxide) were added and kneaded uniformly, and the resulting product was commercially available. A hard capsule was prepared by filling the hard capsule.
レスベラトロール20mgに対し、賦形剤(デンプン、ステアリン酸カルシウム、微粒二酸化ケイ素)480mgを加えて均質に混練し、得られた生成物を市販のハードカプセルに充填することにより、ハードカプセル剤を作製した。 (Comparative Example 1)
To 20 mg of resveratrol, 480 mg of an excipient (starch, calcium stearate, fine silicon dioxide) was added and kneaded homogeneously, and the resulting product was filled into a commercially available hard capsule to prepare a hard capsule.
β-ニコチンアミドモノヌクレオチド40mgに対し、賦形剤(デンプン、ステアリン酸カルシウム、微粒二酸化ケイ素)460mgを加えて均質に混練し、得られた生成物を市販のハードカプセルに充填することにより、ハードカプセル剤を作製した。 (Comparative Example 2)
By adding 460 mg of excipient (starch, calcium stearate, fine silicon dioxide) to 40 mg of β-nicotinamide mononucleotide and kneading homogeneously, the resulting product is filled into a commercially available hard capsule to obtain a hard capsule. Produced.
実施例1及び2で作製した各ハードカプセル剤を、それぞれ血中総コレステロール値が高めの3名の被験者(50歳代)に、1回当たり2カプセル、水又はぬるま湯とともに、1日1回(夕食前)の頻度で4週間(28日間)連続して摂取させた。
一方、比較例1及び2で作製した各ハードカプセル剤を、それぞれ血中総コレステロール値が高めの2名の被験者(50歳代)に、1回当たり2カプセル、水又はぬるま湯とともに、1日1回(夕食前)の頻度で4週間(28日間)連続して摂取させた。
そして、前記ハードカプセル剤の摂取前、及び摂取開始から4週間後に、被験者の血液を採取して、総コレステロール値(mg/dL)を酵素法により測定し、その平均値を求めた。結果を表1に示す。 [Effects on total cholesterol]
Each hard capsule prepared in Examples 1 and 2 was given to 3 subjects (50s) each with a high total blood cholesterol level, once a day with 2 capsules, water or lukewarm water once a day (dinner It was ingested continuously for 4 weeks (28 days) at the frequency of (before).
On the other hand, each hard capsule prepared in Comparative Examples 1 and 2 was given to two subjects (in their 50s) each with a high total blood cholesterol level once daily with 2 capsules, water, or lukewarm water. It was ingested continuously for 4 weeks (28 days) at a frequency of (before dinner).
Then, before ingesting the hard capsule and after 4 weeks from the start of ingestion, the blood of the subject was collected, and the total cholesterol value (mg / dL) was measured by an enzyme method, and the average value was obtained. The results are shown in Table 1.
表1に示した結果からわかるように、実施例1及び2で作製したハードカプセル剤を摂取させると、いずれの場合も総コレステロール値が有意に低下することが認められた。一方、比較例1及び2で作製したハードカプセル剤を摂取させると、いずれの場合も総コレステロール値のわずかな上昇が認められた。このことから、レスベラトロールとニコチンアミドモノヌクレオチドを含む実施例1及び2の食品組成物は、比較例1及び2の食品組成物からは予測できない効果、すなわち、血液中の総コレステロール濃度の低減効果を有することが確認された。 (result)
As can be seen from the results shown in Table 1, it was recognized that when the hard capsules prepared in Examples 1 and 2 were ingested, the total cholesterol value was significantly reduced in both cases. On the other hand, when the hard capsules prepared in Comparative Examples 1 and 2 were ingested, in all cases, a slight increase in the total cholesterol level was observed. Therefore, the food compositions of Examples 1 and 2 containing resveratrol and nicotinamide mononucleotide have effects that cannot be predicted from the food compositions of Comparative Examples 1 and 2, that is, a reduction in the total cholesterol concentration in blood. It was confirmed to have an effect.
実施例1及び2で作製した各ハードカプセル剤を、それぞれ血中低比重リポ蛋白コレステロールが高めの3名の被験者(50歳代)に、1回当たり2カプセル、水又はぬるま湯とともに、1日1回(夕食前)の頻度で4週間(28日間)連続して摂取させた。
一方、比較例1及び2で作製した各ハードカプセル剤を、それぞれ血中低比重リポ蛋白コレステロールが高めの2名の被験者(50歳代)に、1回当たり2カプセル、水又はぬるま湯とともに、1日1回(夕食前)の頻度で4週間(28日間)連続して摂取させた。
そして、前記ハードカプセル剤の摂取前、及び摂取開始から4週間後に、被験者の血液を採取して、低比重リポ蛋白コレステロール(LDLコレステロール)値(mg/dL)を酵素法により測定し、その平均値を求めた。結果を表2に示す。 [Effect on low density lipoprotein cholesterol]
Each hard capsule prepared in Examples 1 and 2 was given to 3 subjects (50s) each with high blood low density lipoprotein cholesterol, once daily with 2 capsules, water or lukewarm water. It was ingested continuously for 4 weeks (28 days) at a frequency of (before dinner).
On the other hand, each hard capsule prepared in Comparative Examples 1 and 2 was given to two subjects (in their 50s) each with high low-density lipoprotein cholesterol in the blood each day with 2 capsules, water, or lukewarm water for 1 day. It was ingested continuously at a frequency of once (before dinner) for 4 weeks (28 days).
Then, before ingesting the hard capsule and 4 weeks after the start of ingestion, the blood of the subject was collected, and the low density lipoprotein cholesterol (LDL cholesterol) value (mg / dL) was measured by an enzymatic method, and the average value thereof Asked. The results are shown in Table 2.
表2に示した結果からわかるように、実施例1及び2で作製したハードカプセル剤を摂取させると、いずれの場合も低比重リポ蛋白コレステロール値が有意に低下することが認められた。一方、比較例1及び2で作製したハードカプセル剤を摂取させると、比較例1ではほとんど変化がなかったが、比較例2では総コレステロール値の上昇が認められた。このことから、レスベラトロールとニコチンアミドモノヌクレオチドを含む実施例1及び2の食品組成物は、比較例1及び2の食品組成物からは予測できない効果、すなわち、血液中の低比重リポ蛋白コレステロール濃度の低減効果を有することが確認された。 (result)
As can be seen from the results shown in Table 2, when the hard capsules prepared in Examples 1 and 2 were ingested, it was recognized that the low specific gravity lipoprotein cholesterol level was significantly reduced in both cases. On the other hand, when the hard capsules prepared in Comparative Examples 1 and 2 were ingested, there was almost no change in Comparative Example 1, but an increase in total cholesterol level was observed in Comparative Example 2. Therefore, the food compositions of Examples 1 and 2 containing resveratrol and nicotinamide mononucleotide have effects that cannot be predicted from the food compositions of Comparative Examples 1 and 2, that is, low-density lipoprotein cholesterol in blood. It was confirmed to have a concentration reducing effect.
実施例1及び2で作製した各ハードカプセル剤を、それぞれ血中中性脂肪値が高めの3名の被験者(50歳代)に、1回当たり2カプセル、水又はぬるま湯とともに、1日1回(夕食前)の頻度で4週間(28日間)連続して摂取させた。
一方、比較例1及び2で作製した各ハードカプセル剤を、それぞれ血中中性脂肪値が高めの2名の被験者(50歳代)に、1回当たり2カプセル、水又はぬるま湯とともに、1日1回(夕食前)の頻度で4週間(28日間)連続して摂取させた。
そして、前記ハードカプセル剤の摂取前、及び摂取開始から4週間後に、被験者の血液を採取して、中性脂肪値(mg/dL)を酵素法により測定し、その平均値を求めた。結果を表3に示す。 [Effects on neutral fat]
Each of the hard capsules prepared in Examples 1 and 2 was given to 3 subjects (in their 50s) each with a high blood neutral fat level once a day with 2 capsules, water or lukewarm water at a time ( It was ingested continuously for 4 weeks (28 days) at a frequency of (before dinner).
On the other hand, each hard capsule prepared in Comparative Examples 1 and 2 was given to two subjects (in their 50s) each with a high blood neutral fat level, with 2 capsules, water or lukewarm water per day. It was ingested continuously for 4 weeks (28 days) at a frequency of twice (before dinner).
Then, before ingesting the hard capsule and 4 weeks after the start of ingestion, the blood of the subject was collected, and the triglyceride level (mg / dL) was measured by an enzyme method, and the average value was obtained. The results are shown in Table 3.
表3に示した結果からわかるように、実施例1及び2で作製したハードカプセル剤を摂取させると、いずれの場合も中性脂肪値が有意に低下することが認められた。一方、比較例1及び2で作製したハードカプセル剤を摂取させると、比較例1は中性脂肪値の上昇が認められ、比較例2は変化がなかった。このことから、レスベラトロールとニコチンアミドモノヌクレオチドを含む実施例1及び2の食品組成物は、比較例1及び2の食品組成物からは予測できない効果、すなわち、血液中の中性脂肪濃度の低減効果を有することが確認された。 (result)
As can be seen from the results shown in Table 3, when the hard capsules prepared in Examples 1 and 2 were ingested, it was recognized that the triglyceride value was significantly reduced in both cases. On the other hand, when the hard capsules prepared in Comparative Examples 1 and 2 were taken, Comparative Example 1 showed an increase in the neutral fat value, and Comparative Example 2 did not change. Therefore, the food compositions of Examples 1 and 2 containing resveratrol and nicotinamide mononucleotide have effects that cannot be predicted from the food compositions of Comparative Examples 1 and 2, that is, the neutral fat concentration in blood. It was confirmed to have a reducing effect.
実施例1で作製した各ハードカプセル剤を、血中尿酸値が高めの2名の被験者(50歳代)に、1回当たり2カプセル、水又はぬるま湯とともに、1日1回(夕食前)の頻度で4週間(28日間)連続して摂取させた。
一方、比較例1及び2で作製した各ハードカプセル剤を、それぞれ血中尿酸値が高めの2名の被験者(50歳代)に、1回当たり2カプセル、水又はぬるま湯とともに、1日1回(夕食前)の頻度で4週間(28日間)連続して摂取させた。
そして、前記ハードカプセル剤の摂取前、及び摂取開始から4週間後に、被験者の血液を採取して、尿酸値(mg/dL)を酵素法により測定し、その平均値を求めた。結果を表4に示す。 [Effects on uric acid]
Each hard capsule prepared in Example 1 was given to two subjects (in their 50s) with high blood uric acid levels once a day (before dinner) with 2 capsules, water or lukewarm water each time. For 4 weeks (28 days).
On the other hand, each hard capsule prepared in Comparative Examples 1 and 2 was given to two subjects (in their 50s) each with a high blood uric acid level once a day with 2 capsules, water or lukewarm water at a time ( It was ingested continuously for 4 weeks (28 days) at a frequency of (before dinner).
Then, before ingesting the hard capsule and 4 weeks after the start of ingestion, the blood of the subject was collected, and the uric acid value (mg / dL) was measured by an enzyme method, and the average value was obtained. The results are shown in Table 4.
表4に示した結果からわかるように、実施例1で作製したハードカプセル剤を摂取させると、尿酸値が有意に低下することが認められた。一方、比較例1及び2で作製したハードカプセル剤を摂取させると、いずれの場合も尿酸値の上昇が認められた。このことから、レスベラトロールとニコチンアミドモノヌクレオチドを含む実施例1の食品組成物は、比較例1及び2の食品組成物からは予測できない効果、すなわち、血液中の尿酸濃度の低減効果を有することが確認された。 (result)
As can be seen from the results shown in Table 4, when the hard capsule prepared in Example 1 was ingested, it was recognized that the uric acid value significantly decreased. On the other hand, when the hard capsules prepared in Comparative Examples 1 and 2 were ingested, an increase in the uric acid level was observed in both cases. From this, the food composition of Example 1 containing resveratrol and nicotinamide mononucleotide has an effect that cannot be predicted from the food compositions of Comparative Examples 1 and 2, that is, an effect of reducing the concentration of uric acid in blood. It was confirmed.
Claims (13)
- レスベラトロールとニコチンアミドモノヌクレオチドを含む食品組成物。 A food composition comprising resveratrol and nicotinamide mononucleotide.
- トリプトファン、及びナイアシンとその代謝物からなる群より選択される1種又は2種以上を含む請求項1に記載の食品組成物。 The food composition according to claim 1, comprising one or more selected from the group consisting of tryptophan and niacin and its metabolites.
- 前記代謝物が、ニコチン酸アデニンジヌクレオチド、ニコチン酸モノヌクレオチド、ニコチンアミドアデニンジヌクレオチド、ニコチンアミドアデニンジヌクレオチドリン酸、ニコチンアミドリボシド及びADPリボースからなる群より選択される1種又は2種以上である請求項2に記載の食品組成物。 The metabolite is one or more selected from the group consisting of nicotinic acid adenine dinucleotide, nicotinic acid mononucleotide, nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate, nicotinamide riboside and ADP ribose The food composition according to claim 2.
- 前記食品組成物の形態が、粉末剤、錠剤、丸剤、顆粒剤、ハードカプセル剤、ソフトカプセル剤、ゼリー剤、液剤、又はペースト剤である、請求項1~3のいずれか1項に記載の食品組成物。 The food according to any one of claims 1 to 3, wherein the food composition is in the form of powder, tablet, pill, granule, hard capsule, soft capsule, jelly, liquid, or paste. Composition.
- レスベラトロールの1日当たりの摂取量が1mg~1000mgであり、ニコチンアミドモノヌクレオチドの1日当たりの摂取量が1mg~100mgの範囲である、請求項1~4のいずれか1項に記載の食品組成物 The food composition according to any one of claims 1 to 4, wherein the daily intake of resveratrol is 1 mg to 1000 mg, and the daily intake of nicotinamide mononucleotide is in the range of 1 mg to 100 mg. object
- 前記食品組成物が、血液中の総コレステロール低減用食品組成物である請求項1~5のいずれか1項に記載の食品組成物 The food composition according to any one of claims 1 to 5, wherein the food composition is a food composition for reducing total cholesterol in blood.
- 前記食品組成物が、血液中の低比重リポ蛋白コレステロール低減用食品組成物である請求項1~5のいずれか1項に記載の食品組成物 The food composition according to any one of claims 1 to 5, wherein the food composition is a food composition for reducing low density lipoprotein cholesterol in blood.
- 前記食品組成物が、血液中の中性脂肪低減用食品組成物である請求項1~5のいずれか1項に記載の食品組成物 The food composition according to any one of claims 1 to 5, wherein the food composition is a food composition for reducing neutral fat in blood.
- 前記食品組成物が、血液中の尿酸低減用食品組成物である請求項1~5のいずれか1項に記載の食品組成物 The food composition according to any one of claims 1 to 5, wherein the food composition is a food composition for reducing uric acid in blood.
- 請求項1~5のいずれか1項に記載の食品組成物を摂取させる、血液中の総コレステロールを低減する方法(ヒトに対する医療行為を除く。)。 A method for reducing the total cholesterol in blood by ingesting the food composition according to any one of claims 1 to 5 (excluding medical practice for humans).
- 請求項1~5のいずれか1項に記載の食品組成物を摂取させることを特徴とする、血液中の低比重リポ蛋白コレステロールを低減する方法(ヒトに対する医療行為を除く。)。 A method for reducing low-density lipoprotein cholesterol in blood (excluding medical practice for humans), which comprises ingesting the food composition according to any one of claims 1 to 5.
- 請求項1~5のいずれか1項に記載の食品組成物を摂取させることを特徴とする、血液中の中性脂肪を低減する方法(ヒトに対する医療行為を除く。)。 A method for reducing neutral fat in blood (excluding medical practice for humans), which comprises ingesting the food composition according to any one of claims 1 to 5.
- 請求項1~5のいずれか1項に記載の食品組成物を摂取させることを特徴とする、血液中の尿酸を低減する方法(ヒトに対する医療行為を除く。)。 A method for reducing uric acid in blood (excluding medical practice for humans), which comprises ingesting the food composition according to any one of claims 1 to 5.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017509446A JP6545256B2 (en) | 2015-03-31 | 2016-03-07 | Food composition comprising resveratrol and nicotinamide mononucleotide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-071150 | 2015-03-31 | ||
JP2015071150 | 2015-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016158212A1 true WO2016158212A1 (en) | 2016-10-06 |
Family
ID=57006686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/056943 WO2016158212A1 (en) | 2015-03-31 | 2016-03-07 | Food composition containing resveratrol and nicotinamide mononucleotide |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6545256B2 (en) |
WO (1) | WO2016158212A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017062311A1 (en) | 2015-10-07 | 2017-04-13 | Huizenga Joel | Resetting biological pathways for defending against and repairing deterioration from human aging |
WO2019044348A1 (en) * | 2017-08-30 | 2019-03-07 | アサヒグループホールディングス株式会社 | Composition for decreasing serum uric acid level |
CN109589309A (en) * | 2017-09-30 | 2019-04-09 | 浙江嘉华化工有限公司 | The preparation method of niacinamide ribose micro-capsule |
CN112089705A (en) * | 2020-09-28 | 2020-12-18 | 深圳雾件科技有限公司 | Nicotinamide mononucleotide microcapsule and preparation method thereof |
CN112155186A (en) * | 2020-11-11 | 2021-01-01 | 北京斯利安药业有限公司 | Composition for resisting oxidation and/or delaying aging, application and product thereof |
CN112515070A (en) * | 2020-11-11 | 2021-03-19 | 云南爱尔康生物技术有限公司 | Sports beverage containing astaxanthin, taurine, nicotinamide mononucleotide and electrolyte and preparation method thereof |
CN113832204A (en) * | 2021-09-22 | 2021-12-24 | 杭州吾尾科技有限公司 | NMN preparation method and NMN-containing dog and cat anti-aging health product formula |
JP7026422B1 (en) | 2021-06-30 | 2022-02-28 | ドリームパワー株式会社 | Beverage |
WO2022101501A1 (en) * | 2020-11-16 | 2022-05-19 | Scandibio Therapeutics Ab | Substances for treatment of hyperuricaemia |
JP7168279B1 (en) * | 2021-12-20 | 2022-11-09 | ドリームパワー株式会社 | Liquid compositions and sirtuin-activating compositions |
JP7287587B1 (en) * | 2023-01-18 | 2023-06-06 | 大正製薬株式会社 | solid composition |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113181205B (en) * | 2021-04-19 | 2023-07-14 | 苏州人本药业有限公司 | Pharmaceutical composition comprising NMN and use thereof |
TWI832388B (en) * | 2022-08-22 | 2024-02-11 | 睿創健康股份有限公司 | Whitening health care composition |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006001982A2 (en) * | 2004-06-04 | 2006-01-05 | Washington University | Methods and compositions for treating neuropathies |
WO2007008548A2 (en) * | 2005-07-07 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
US20100254962A1 (en) * | 2007-10-24 | 2010-10-07 | Karl Zehethofer | Functional drink |
-
2016
- 2016-03-07 WO PCT/JP2016/056943 patent/WO2016158212A1/en active Application Filing
- 2016-03-07 JP JP2017509446A patent/JP6545256B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006001982A2 (en) * | 2004-06-04 | 2006-01-05 | Washington University | Methods and compositions for treating neuropathies |
WO2007008548A2 (en) * | 2005-07-07 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
US20100254962A1 (en) * | 2007-10-24 | 2010-10-07 | Karl Zehethofer | Functional drink |
Non-Patent Citations (3)
Title |
---|
PALSAMY P. ET AL.: "Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats", BIOMED. PHARMACOTHER., vol. 62, no. 9, November 2008 (2008-11-01), pages 598 - 605, XP025571995 * |
SHI Y. W. ET AL.: "Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice", MOL. NUTR. FOOD RES., vol. 56, no. 9, September 2012 (2012-09-01), pages 1433 - 1444, XP055319533 * |
SHINKOWA TRADING CO., LTD.: "NMN Haigo Supplement", PRESS RELEASE, 22 April 2015 (2015-04-22), XP055319534, Retrieved from the Internet <URL:https://www.atpress.ne.jp/news/print/window/popup/pr_id/60629/> [retrieved on 20160509] * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017062311A1 (en) | 2015-10-07 | 2017-04-13 | Huizenga Joel | Resetting biological pathways for defending against and repairing deterioration from human aging |
JP2018530614A (en) * | 2015-10-07 | 2018-10-18 | ハイゼンガ,ジョエル | Resetting biological pathways to protect against human aging and to repair its degradation |
EP3359259A4 (en) * | 2015-10-07 | 2019-04-24 | Huizenga, Joel | Resetting biological pathways for defending against and repairing deterioration from human aging |
WO2019044348A1 (en) * | 2017-08-30 | 2019-03-07 | アサヒグループホールディングス株式会社 | Composition for decreasing serum uric acid level |
JP6492236B1 (en) * | 2017-08-30 | 2019-03-27 | アサヒグループホールディングス株式会社 | Composition for reducing serum uric acid level |
US11173143B2 (en) | 2017-08-30 | 2021-11-16 | Asahi Group Holdings, Ltd. | Composition for decreasing serum uric acid level |
CN109589309A (en) * | 2017-09-30 | 2019-04-09 | 浙江嘉华化工有限公司 | The preparation method of niacinamide ribose micro-capsule |
CN112089705A (en) * | 2020-09-28 | 2020-12-18 | 深圳雾件科技有限公司 | Nicotinamide mononucleotide microcapsule and preparation method thereof |
CN112515070A (en) * | 2020-11-11 | 2021-03-19 | 云南爱尔康生物技术有限公司 | Sports beverage containing astaxanthin, taurine, nicotinamide mononucleotide and electrolyte and preparation method thereof |
CN112155186A (en) * | 2020-11-11 | 2021-01-01 | 北京斯利安药业有限公司 | Composition for resisting oxidation and/or delaying aging, application and product thereof |
WO2022101501A1 (en) * | 2020-11-16 | 2022-05-19 | Scandibio Therapeutics Ab | Substances for treatment of hyperuricaemia |
EP4000611A1 (en) * | 2020-11-16 | 2022-05-25 | ScandiBio Therapeutics AB | Substances for treatment of hyperuricaemia |
JP7026422B1 (en) | 2021-06-30 | 2022-02-28 | ドリームパワー株式会社 | Beverage |
JP2023006363A (en) * | 2021-06-30 | 2023-01-18 | ドリームパワー株式会社 | beverage |
CN113832204A (en) * | 2021-09-22 | 2021-12-24 | 杭州吾尾科技有限公司 | NMN preparation method and NMN-containing dog and cat anti-aging health product formula |
JP7168279B1 (en) * | 2021-12-20 | 2022-11-09 | ドリームパワー株式会社 | Liquid compositions and sirtuin-activating compositions |
JP7287587B1 (en) * | 2023-01-18 | 2023-06-06 | 大正製薬株式会社 | solid composition |
Also Published As
Publication number | Publication date |
---|---|
JPWO2016158212A1 (en) | 2018-02-22 |
JP6545256B2 (en) | 2019-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016158212A1 (en) | Food composition containing resveratrol and nicotinamide mononucleotide | |
US11219590B2 (en) | Anti-aging agent and anti-aging method | |
EP3513796A1 (en) | Sleep disorder improvement agent and method for improving sleep disorders | |
EP3850954A1 (en) | Anti-aging agent and anti-aging method | |
EP3513795B1 (en) | Visual function improvement agent, and method for improving visual function | |
JP5121308B2 (en) | Composition for preventing, improving or treating metabolic syndrome | |
JP2009543883A (en) | Quercetin-containing composition | |
JP6335508B2 (en) | Growth hormone secretagogue | |
KR20070039924A (en) | Pomegranate juice, pomegranate juice powder and process for producing the powder | |
JP2008297209A (en) | Lipid metabolism-improving composition | |
KR20140090453A (en) | Composition comprising aronia extract for preventing and relieving hangover, and for protecting the alcohol-damaged hepatocyte | |
EP4122536A1 (en) | Coenzyme q production promoter and coenzyme q production promoting method | |
JP2005185188A (en) | Composition containing treated product of acerola and l-carnitine | |
JP5545692B2 (en) | Xanthine oxidase inhibitor and plasma uric acid level-lowering agent | |
JP2009084198A (en) | Aldose reductase inhibitor | |
JP2007000081A (en) | Food for improving lipid metabolism | |
KR20130112236A (en) | Composition for inhibiting high glucose-induced inflammatory comprising sodium butyrate as an active ingredient | |
JP2009298759A (en) | alpha-AMYLASE INHIBITOR | |
JP2005139093A (en) | Glucose absorption inhibitor and its manufacturing method thereof | |
KR20170065117A (en) | Composition for preventing, improving or treating vascular diseases comprising 3-caffeoyl-4-dihydrocaffeoylquinic acid as effective component | |
EP4309515A1 (en) | Composition for promoting glp-1 secretion | |
JP2011132173A (en) | Xanthine oxidase inhibitor and uric acid production inhibitor | |
JP2022098492A (en) | Composition for improving intracerebral biosynthesis of mitochondria | |
JP5406085B2 (en) | Helicobacter pylori adhesion inhibitor | |
JP2009051751A (en) | Muscle cell sugar transport promotion action composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16772096 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017509446 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 09.01.2018) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16772096 Country of ref document: EP Kind code of ref document: A1 |